Figs Inc Dossier - Source-backed chat

Figs Inc

FIGSNYSE

SectorConsumer Discretionary

IndustryApparel Manufacturing

Beta (adjusted)1.01

Intrinsic Value $18.43median of 6 methods · middle span $11-$25based on filings through 30 Jun 2026

Market Price $14.08Price as of 1 Oct 2026

UndervaluedIntrinsic value is 31% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $2.3B

Enterprise Value $2.2B

Shares Outstanding 166.1M diluted

Moat Rating Wide

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

FIGS, Inc. is the category-defining direct-to-consumer (DTC) healthcare apparel and lifestyle brand, successfully disrupting a highly fragmented global medical uniforms market. The company's investment thesis is anchored by its strong brand equity, highly loyal customer base, and robust financial profile characterized by high gross margins and a debt-free balance sheet. Following a stellar Q1 2026 performance where active customers surpassed 3.0 million for the first time and net revenues grew 28% YoY, FIGS has demonstrated a powerful return to profitability and operating leverage. Management's upward revision of FY2026 revenue growth guidance to 14%-16% and adjusted EBITDA margin to 13.0%-13.2% underscores strong operational momentum. Key growth catalysts include international expansion (which grew 49.9% in Q1 2026), the scaling of the institutional B2B 'TEAMS' platform, and product category diversification into non-scrubwear layering systems and footwear.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$15.00

Mean target$18.63

High · most bullish analyst$22.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$15.0015%

In the bear case, intense competition from legacy uniform suppliers and athletic apparel giants (such as Nike and Lululemon entering the medical apparel space) pressures market share and forces promotional discounting, eroding gross margins. Severe supply chain disruptions or unmitigated tariff impacts exceeding 300 basis points compress profitability. Additionally, rising customer acquisition costs (CAC) and slower-than-expected adoption of the TEAMS platform limit top-line growth to the single digits, leading to multiple contraction.

Base CaseCentral scenario

$18.6360%

Matches the consensus mean

The base case assumes FIGS successfully executes on its revised FY2026 guidance, delivering net revenue growth of 14% to 16% and achieving an adjusted EBITDA margin of 13.0% to 13.2%. Active customer growth continues at a steady double-digit pace, supported by strong repeat customer dynamics and moderate international scaling. Gross margins remain stable in the mid-60s as the company absorbs planned tariff headwinds through pricing power and sourcing optimization, while maintaining a solid net cash position.

Bull CaseUpside scenario

$22.0025%

In the bull case, FIGS accelerates its international expansion across its 85-country footprint, and its institutional B2B 'TEAMS' platform gains rapid market share, driving revenue growth well above the raised guidance. Product innovation in non-scrubwear and footwear successfully increases average order value (AOV) and purchase frequency. Operational efficiencies and successful tariff mitigation strategies in Vietnam and Jordan allow gross margins to expand back toward historical high-60s, while fixed-cost leverage drives adjusted EBITDA margins above 15%.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Category-defining brand with an exceptionally loyal community of over 3.0 million active healthcare professionals.
Direct-to-consumer (DTC) model driving superior gross margins (67.7% in Q1 2026) compared to traditional apparel peers.
Strong balance sheet with $277 million in cash, cash equivalents, and short-term investments, and zero debt.
High-growth international opportunity, with international revenues growing 49.9% YoY in Q1 2026.
Untapped institutional B2B market potential through the proprietary TEAMS platform.

Key Investment Risks

Significant tariff headwinds, particularly unmitigated impacts from Section 301 tariffs, which pressure gross margins.
Intensifying competition from legacy medical uniform brands and athletic apparel incumbents expanding into technical medical wear.
Inventory management risks, including potential write-offs of aged inventory and supply chain sourcing concentration.
Sensitivity to macroeconomic cycles and inflationary pressures on raw materials and shipping costs.

Thesis Invalidation Triggers

A sustained decline in active customer growth or a contraction in net revenues per active customer.
Gross margin compression below 62% driven by unmitigated tariff increases or aggressive promotional discounting.
Failure to scale the B2B TEAMS platform, resulting in stagnant institutional market penetration.
Significant market share loss to athletic apparel competitors entering the technical medical wear segment.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.